SGI-1776A potent apoptotic that targets Pim and FLT3 in AML and CLL cells

SGI-1776 (CAS 1025065-69-3)

SGI-1776 | CAS 1025065-69-3 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_22, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364615, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 79ms
  • REVIEWS, PRODUCT
Synonym: SGI-1776 free base
Application: A potent apoptotic that targets Pim and FLT3 in AML and CLL cells
CAS Number: 1025065-69-3
Purity: ≥98%
Molecular Weight: 405.42
Molecular Formula: C20H22F3N5O
* Refer to Certificate of Analysis for lot specific data (including water content).
submit a review for this product and receive 15 cruzcredits

SGI-1776 is a novel ATP-competitive inhibitor of Pim-1, Pim-2, and Pim-3 (IC50 = 7, 363, and 69 nM, respectively). In addition to inhibiting Pim, this compound also inhibits FLT3 (IC50 = 44 nM). SGI-1776 is also cytotoxic in AML primary cells, regardless of the FLT3 mutation status, which results in Mcl-1 protein decline. SGI-1776 inhibits tumor growth for intermediate EFS T/C activity in 1 of 39 evaluable models.

Physical State :
Solid
Storage :
Store at -20° C
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.61 (Predicted)
pK Values :
pKb: 8.93 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
24795070
SMILES :
CN1CCC(CC1)CNC2=NN3C(=NC=C3C4=CC(=CC=C4)OC(F)(F)F)C=C2

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

SGI-1776  Product Citations

See how others have used SGI-1776. Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 25263741  Taniguchi, H. et al. 2014. Cancer science. 105: 1601-8.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 81ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Cervantes Cervantes-Gomez et al. (PubMed ID 26088877) found that the Pim kinase inhibitor, SGI-1776, combined with Bcl-2 antagonists in malignant chronic lymphocytic leukemia lymphocytes resulted in additive cytotoxicity. -SCBT Publication Review
Date published: 2015-01-22
  • y_2019, m_9, d_22, h_9
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364615, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 5ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.